Unum’s T-Cell Therapy Enters Phase 1 Trial for Relapsed or Refractory Multiple Myeloma

The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug (IND) application filed by Unum Therapeutics for its ACTR087 T-cell therapy…